TCR2
Cambridge
About TCR2
TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $297.3M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jul 2020)
- Ticker: nasdaq:TCRR
- Website: tcr2.com
- Phone: 617.475.8469
Industries & Categories
Biotechnology, Health Care, Life Science, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/tcr2-40545 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.